US 7364736B2

The Google Patents link for US7364736B2 (Source 1, 2) provides all the requested information about the patent itself, including the abstract.

I found multiple District Court cases filed in New Jersey and Massachusetts District Courts related to the patent family (Source 1). However, my search for "US7364736B2 CAFC dockets 2026" did not yield any specific CAFC cases for this patent in 2026. The result is a general page about CAFC case information, and discusses a different patent case (Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc.) at the Federal Circuit in May 2026, which is not relevant to US7364736B2. Therefore, I will state that no CAFC dockets for 7364736B2 were found for 2026.

Now, I will extract the information and summarize the independent claims.

Title: Antibodies to OPGL
Assignee: Amgen Inc.
Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
Filing Date: 2002-06-25
Issue Date: 2008-04-29
Abstract: The present invention relates to antibodies that bind osteoprotegerin ligand (OPGL). Compositions and methods for the treatment of bone diseases, such as osteoporosis, bone loss from arthritis, Paget's disease, and osteopenia, are also described. Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

Now, I need to go through the patent text to identify and paraphrase the independent claims. I will scroll down to the "Claims" section of the provided patent text.

The patent has 20 claims. I need to identify the independent claims and provide a plain-language overview of each.

Claim 1: "1. An isolated antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2 or a fragment thereof, and the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 4 or a fragment thereof."

Claim 10: "10. A pharmaceutical composition, comprising an antibody according to claim 1, and at least one therapeutic agent selected from a bone morphogenic factor, transforming growth factor-β (TGF-β), an interleukin-1 (IL-1) inhibitor, a TNFα inhibitor, a parathyroid hormone, an analog of a parathyroid hormone, a parathyroid hormone related protein, an analog of a parathyroid hormone related protein, a prostaglandin, a bisphosphonate, fluoride, calcium, a non-steroidal anti-inflammatory drug (NSAID), a COX-2 inhibitor, an immunosuppressant, and an IL-18 inhibitor." - This depends on claim 1. So it's not an independent claim in the strict sense, but it introduces a new concept of a pharmaceutical composition. I will treat it as a significant claim that adds to the scope of the invention.

Claim 11: "11. A method of treating an osteopenic disorder in a patient, comprising administering to the patient a therapeutically effective amount of an antibody according to claim 1." - This depends on claim 1.

Claim 12: "12. A method of treating an inflammatory condition with attendant bone loss in a patient, comprising administering to the patient a therapeutically effective amount of an antibody according to claim 1." - This depends on claim 1.

Claim 13: "13. A method of treating an autoimmune condition with attendant bone loss in a patient, comprising administering to the patient a therapeutically effective amount of an antibody according to claim 1." - This depends on claim 1.

Claim 14: "14. A method of treating rheumatoid arthritis in a patient, comprising administering to the patient a therapeutically effective amount of an antibody according to claim 1." - This depends on claim 1.

Claim 15: "15. A method of detecting the level of OPGL in a biological sample, comprising contacting the sample with an antibody according to claim 1." - This depends on claim 1.

Claim 16: "16. A method of treating multiple myeloma in a patient, comprising administering to the patient a therapeutically effective amount of an antibody according to claim 1." - This depends on claim 1.

Claim 17: "17. A method of treating bone loss due to metastatic cancer in a patient, comprising administering to the patient a therapeutically effective amount of an antibody according to claim 1." - This depends on claim 1.

Claim 18: "18. An isolated polynucleotide encoding a heavy chain of an antibody, wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2."

Claim 19: "19. An isolated polynucleotide encoding a light chain of an antibody, wherein the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 4."

Claim 20: "20. A host cell comprising the polynucleotide of claim 18 or claim 19."

Let's re-examine the claims to identify only the independent claims.
Independent claims: 1, 18, 19, 20.

I also need to check for other claims that could be independent, for example, if they start with "An antibody..." and don't refer to a previous claim. However, scanning the definitions section, the initial descriptions of the invention also outline different forms of the antibody that could be considered independent if they were claimed as such. Let's make sure I capture all truly independent claims from the claims section itself.

Reading the patent text's "Definitions" section, it states:
"the invention provides for an antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2 or a fragment thereof, and the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 4 or a fragment thereof." This is claim 1.
"the invention provides for an antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable region comprising an amino acid sequence as set forth in SEQ ID NO: 13 or a fragment thereof, and wherein the light chain comprises a variable region comprising an amino acid sequence as set forth in SEQ ID NO: 14 or a fragment thereof." This is not an explicit claim, but a description of what the invention provides.
"the invention provides for an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 2 or a fragment thereof." This is not an explicit independent claim.
"the invention provides for an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable region comprising an amino acid sequence as set forth in SEQ ID NO: 13 or a fragment thereof." Not an explicit independent claim.
"the invention provides for an antibody comprising a heavy chain and a light chain, wherein the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 4 or a fragment thereof." Not an explicit independent claim.
"the invention provides for an antibody comprising a heavy chain and a light chain, wherein the light chain comprises a variable region comprising an amino acid sequence as set forth in SEQ ID NO: 14 or a fragment thereof." Not an explicit independent claim.
"the invention provides for an antibody, comprising a heavy chain and a light chain, (a) wherein the heavy chain comprises a first variable region, and wherein the first variable region comprises a sequence that has at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 13, and (b) wherein the light chain comprises a second variable region, and wherein the second variable region comprises a sequence that has at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 14, and (c) wherein the antibody interacts with an osteoprotegerin ligand (OPGL)." This is a broader description of the invention.

I need to stick to the actual numbered claims section to identify independent claims.

The independent claims are indeed 1, 18, 19, and 20.

Plain-language overview of each independent claim:

• Claim 1: This claim covers an isolated antibody. This antibody must include a heavy chain that has the amino acid sequence specified in SEQ ID NO: 2 (or a fragment of it) and a light chain that has the amino acid sequence specified in SEQ ID NO: 4 (or a fragment of it).
• Claim 18: This claim covers an isolated polynucleotide (a DNA or RNA sequence) that contains the genetic code for the heavy chain of an antibody, where that heavy chain has the amino acid sequence of SEQ ID NO: 2.
• Claim 19: This claim covers an isolated polynucleotide that contains the genetic code for the light chain of an antibody, where that light chain has the amino acid sequence of SEQ ID NO: 4.
• Claim 20: This claim covers a host cell (a living cell, e.g., for manufacturing) that contains either the polynucleotide from Claim 18 or the polynucleotide from Claim 19.

The search for CAFC dockets explicitly for "US7364736B2 CAFC dockets 2026" did not return specific results, as noted in the previous step. The litigation mentioned on Google Patents (Source 1) points to district court cases, not necessarily CAFC cases yet, and not specifically for 2026. Therefore, I will state that no CAFC dockets for 2026 were found for this specific patent.US Patent 7364736B2, titled "Antibodies to OPGL," was assigned to Amgen Inc.. The inventors are William J. Boyle, Francis H. Martin, Jose R. Corvalan, and C. Geoffrey Davis. The patent was filed on June 25, 2002, and issued on April 29, 2008.

The abstract of the patent describes antibodies that bind to osteoprotegerin ligand (OPGL). It also details compositions and methods for treating bone diseases such as osteoporosis, bone loss associated with arthritis, Paget's disease, and osteopenia. Furthermore, the patent describes methods for detecting OPGL levels in a sample using these antibodies.

As of the current date, May 29, 2026, no specific cases for US7364736B2 have been identified in the CAFC 2026 dockets.

Here is a plain-language overview of each independent claim:

• Claim 1: This claim covers a specific, isolated antibody. This antibody is defined by having a heavy chain with an amino acid sequence matching SEQ ID NO: 2 (or a part of it) and a light chain with an amino acid sequence matching SEQ ID NO: 4 (or a part of it).
• Claim 18: This claim covers an isolated polynucleotide (which is a nucleic acid like DNA or RNA) that contains the genetic instructions for producing the heavy chain of an antibody, specifically the heavy chain with the amino acid sequence as set forth in SEQ ID NO: 2.
• Claim 19: This claim covers an isolated polynucleotide that contains the genetic instructions for producing the light chain of an antibody, specifically the light chain with the amino acid sequence as set forth in SEQ ID NO: 4.
• Claim 20: This claim covers a host cell (a cell used for genetic engineering or production) that contains either the polynucleotide described in Claim 18 or the polynucleotide described in Claim 19.